文献速递前列腺增生与排尿功能障碍

非索罗定治疗膀胱过度活动症患者夜间尿急:应答者与无应答者分析

Fesoterodine for the Treatment of Nocturnal Urgency in Patients with Overactive Bladder Syndrome: An Analysis of Responders and Nonresponders.
PubMed 文献 · J Urol · 2017-05-04

本研究基于一项为期12周的双盲随机对照试验数据,分析膀胱日记参数以预测膀胱过度活动症伴夜间尿急患者对非索罗定的应答。结果显示,夜间膀胱容量指数与夜尿指数和应答可能性呈线性关系,应答者夜间尿量较基线显著减少(-181.7 ml,p<0.01),且症状改善与生活质量改善相关。

要点

  • 夜间膀胱容量指数与夜尿指数和成为应答者的可能性呈线性关系。
  • 应答者夜间尿量较基线显著减少(-181.7 ml,p<0.01)。
  • 应答者夜间膀胱容量指数和夜尿指数显著下降(分别-0.82和-0.61,各p<0.01)。

核心结论

  • 继发于膀胱过度活动症的夜间尿急且夜间膀胱容量低、夜间尿量与膀胱容量不匹配的患者可能从非索罗定中获益。
  • 症状改善似乎由典型而非最大夜间排尿量的增加所介导。
  • 症状改善与生活质量改善相关。

研究设计与样本

  • 患者先接受2周单盲安慰剂导入期,随后按1:1双盲随机分配至12周非索罗定或安慰剂治疗。
  • 分析膀胱日记参数从基线至第12周的变化,包括实际夜尿次数(夜尿症总次数)、最大排尿量、夜间膀胱容量、夜间膀胱容量指数(NBCi)、夜间尿量、夜尿指数和夜间多尿指数,并分析OAB-q变化。

主要发现

  • 夜间膀胱容量指数与夜尿指数和成为应答者的可能性之间存在线性关系。
  • 应答者夜间尿量较基线显著减少(-181.7 ml,p<0.01)。
  • 两组最大排尿量较基线均无显著变化。
  • 应答者夜间膀胱容量指数和夜尿指数显著下降(分别-0.82和-0.61,各p<0.01)。
  • 应答者在OAB-q的关注、应对、睡眠、困扰和总分指标上均有改善。

临床怎么用

  • 作者认为,继发于膀胱过度活动症的夜间尿急且夜间膀胱容量低、夜间尿量与膀胱容量不匹配的患者可能从非索罗定中获益。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: A recent study demonstrated improvement in nocturnal urgency in patients with overactive bladder when treated with fesoterodine. In the current study we aimed to determine which bladder diary parameters predict the response to fesoterodine in these patients. MATERIALS AND METHODS: Patients with nocturnal urgency completed a 2-week, single-blind placebo run-in followed by 1:1 double-blind randomization to 12 weeks of fesoterodine or placebo. We analyzed bladder diary parameter changes from baseline to week 12, including the actual number of night voids (total number of nocturia episodes), maximum voided volume, nocturnal bladder capacity, Nocturnal Bladder Capacity Index (NBCi) (actual number of night voids - nocturnal urine volume/maximum voided volume - 1), nocturnal urine volume, the nocturia index (nocturnal urine volume/maximum voided volume) and the nocturnal polyuria index (nocturnal urine volume/24-hour volume). Additionally, we analyzed OAB-q (Overactive Bladder Questionnaire) changes. RESULTS: There was a linear relationship between the likelihood of being a responder for NBCi and the nocturia index. Responders had a significant decrease in nocturnal urine volume relative to baseline (-181.7 ml, p <0.01). Neither group showed a significant change in maximum voided volume relative to baseline. There was a significant decrease in NBCi and the nocturia index in responders (-0.82 and -0.61, respectively, each p <0.01). Responders demonstrated improvement in the OAB-q concern, coping, sleep, bother and total score metrics. CONCLUSIONS: Patients with nocturnal urgency secondary to overactive bladder syndrome and low nocturnal bladder capacity with a mismatch between nocturnal urine production and bladder capacity may benefit from fesoterodine. Symptom improvement appears to be mediated by increases in typical rather than maximum nocturnal voided volumes. Symptom improvement was associated with improved quality of life.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Khusid JA, Weiss JP, Carlsson MO, et al. Fesoterodine for the Treatment of Nocturnal Urgency in Patients with Overactive Bladder Syndrome: An Analysis of Responders and Nonresponders. J Urol. 2017. PMID: 28479240. doi:10.1016/j.juro.2017.04.098

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。